Larry J Copeland MD

Larry J Copeland MD
ProfessorCollege of Medicinecopeland.7@osu.edu
M210 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7642Fax: 614-293-5877
  • Translational Therapeutics

Current Publications

  • Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJA phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.Gynecol Oncol in press 6/5/2014
  • Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer ELFeasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.Int J Gynecol Cancer 24 682-6 5/1/2014
  • Landrum LM, Java J, Mathews CA, Lanneau GS, Copeland LJ, Armstrong DK, Walker JLPrognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.Gynecol Oncol 130 12-8 7/1/2013
  • Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23 833-8 6/1/2013
  • McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129 135-9 4/1/2013
  • Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129 103-6 4/1/2013
  • McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128 44-8 1/1/2013
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA, National Comprehensive Cancer NetworkOvarian cancer, version 3.2012.J Natl Compr Canc Netw 10 1339-49 11/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu